NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 4 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Subsidiary JAEL Signs SSPA for 40% Stake in Zettaone Technologies, Option to Raise to 51%
Jubilant Ingrevia's wholly owned subsidiary, Jubilant Advanced Electronics Limited (JAEL), has executed a Share Subscription and Share Purchase Agreement (SSPA) to acquire an initial 40% strategic equity stake in Zettaone Technologies India Private Limited. The agreement includes an option to increase the holding to 51% in FY28. This transaction marks Jubilant Ingrevia's entry into the Electronics Design and Manufacturing Services (EDMS) sector to support semiconductor, aerospace, defense, and automotive verticals. Specific deal valuation and consideration were not disclosed in this filing, as key terms were reported in a prior communication dated October 1, 2026.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுJAEL formalised the acquisition of a 40% stake in Zettaone Technologies by signing the definitive SSPA, securing an option to raise stake to 51% by FY28.
ஏன் இது முக்கியம்It establishes Jubilant Ingrevia's strategic footprint in the high-growth EDMS space, creating forward integration synergies with its semiconductor and electronics chemicals business.
📅 குறுகிய காலம்Sentimentally positive as the company executes on its diversification into semiconductor-linked electronics manufacturing, though financial impact remains unquantified until deal values are consolidated.
📈 நீண்ட காலம்Provides an integrated platform combining chemical CDMO with EDMS design capabilities, aligning with Jubilant's broader strategic push into high-tech semiconductor materials.
⚠ அபாய எச்சரிக்கைகள்
Financial outlay and acquisition valuation not disclosed in this filing
Integration risk entering the non-core electronics design and manufacturing services (EDMS) space
👀 கவனிக்க வேண்டியவை
Track subsequent filings for the completion of acquisition milestones and disclosure of the final cash outlay relative to the company's net worth (Rs 2,640 Cr).
Q2 FY27 Transcript: Jubilant Ingrevia Revenue Up 24% to ₹1,394 Cr, Acquires 40% Stake in Zettaone
Jubilant Ingrevia reported record quarterly revenue of ₹1,394 crore for Q2 FY27, up 24% year-on-year, while EBITDA jumped 51% YoY to ₹221 crore. Net profit expanded 60% YoY to ₹111 crore, supported by strong performance in Specialty Chemicals (revenue ₹560 crore, 25% margin) and Nutrition (revenue up 50% to ₹270 crore). The company also announced the acquisition of a 40% stake in Zettaone Technologies to expand into the electronics and semiconductor chemicals ecosystem. Management guided that the new Multi-Purpose Plant (MPP) remains on track for commissioning by the end of the year.
உச்சம் நம்பிக்கை
என்ன மாறியதுJubilant Ingrevia filed the transcript of its Q2 & H1 FY27 earnings call held on October 27, 2026, detailing operational progress and the strategic acquisition of a 40% stake in Zettaone Technologies.
ஏன் இது முக்கியம்Demonstrates operational turnaround with 51% EBITDA growth and expands reach into high-margin electronics and semiconductor chemicals through strategic integration.
📅 குறுகிய காலம்Earnings transcript provides positive detail on margin expansion, though management flagged seasonal pricing softness in Vitamin B3 for Q3.
📈 நீண்ட காலம்The company's Pinnacle strategy targeting multi-fold revenue growth is bolstered by the 25+ molecule pipeline, CDMO contracts, and semiconductor integration via Zettaone.
⚠ அபாய எச்சரிக்கைகள்
Pricing softness in base pyridine and vitamin B3 feed segment
Agrochemical sector margin pressure from excess Chinese capacity
👀 கவனிக்க வேண்டியவை
Track the commissioning and commercial ramp-up of the new Multi-Purpose Plant scheduled for year-end, along with pricing trends in Vitamin B3.
Q2 FY27 PAT Jumps 61% YoY to ₹111 Cr; Signs ₹189.2 Cr Deal for 40% Stake in ZettaOne
Jubilant Ingrevia reported strong Q2 FY27 performance, with revenue growing 24% YoY to ₹1,394 crore and EBITDA increasing 51% YoY to ₹221 crore (16% margin). Net profit rose 61% YoY to ₹111 crore, supported by double-digit volume growth in Nutrition and sharp margin recovery in Chemical Intermediates (EBITDA up 226% YoY). Additionally, the company signed an agreement to acquire a 40% stake in ZettaOne Technologies for ₹189.2 crore (approx. 4.1% of TTM revenue), marking its foray into electronics manufacturing (EDMS).
உச்சம் நம்பிக்கை
என்ன மாறியதுJubilant Ingrevia delivered record quarterly operational performance for Q2 FY27 and announced an acquisition agreement for a 40% stake in ZettaOne Technologies for ₹189.2 crore.
ஏன் இது முக்கியம்Demonstrates accelerating operating leverage and profitability under the Pinnacle strategy, while diversifying the revenue base into high-margin electronics and semiconductor chemicals.
📅 குறுகிய காலம்Strong operational beat across segments, coupled with margin expansion to 16%, is likely to drive positive sentiment in the immediate term.
📈 நீண்ட காலம்Entry into the semiconductor and EDMS ecosystems alongside the upcoming Multi-Purpose Plant positions the company well to sustain its 5-year growth trajectory under the Pinnacle plan.
⚠ அபாய எச்சரிக்கைகள்
Higher input and utility costs partially offsetting realizations
Continued pricing softness in Vitamin B3 feed grade and Pyridine/Picolines
Integration and execution risk regarding the ZettaOne EDMS investment
👀 கவனிக்க வேண்டியவை
Track the commissioning of the new Multi-Purpose Plant (MPP) slated for late 2026 and monitor the closing of the ZettaOne acquisition alongside European market share gains in Acetic Anhydride.
Jubilant Ingrevia Limited announced that its Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The meeting commenced at 11:10 AM and concluded at 2:00 PM on October 27, 2026. Detailed numerical P&L figures were enclosed separately via the Limited Review Report and were not detailed in the cover letter text. Investors should review the detailed result tables for revenue and margin progression against previous quarter revenue of Rs 1,300.27 Cr.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுFormal board approval and release of Q2 and H1 FY27 financial results.
ஏன் இது முக்கியம்Provides updated operational and financial performance visibility for Jubilant Ingrevia's specialty chemicals and CDMO segments.
📅 குறுகிய காலம்Market reaction will depend on the detailed revenue and net profit figures relative to trailing performance and consensus expectations.
📈 நீண்ட காலம்Limited from this procedural cover note; execution of the 'Pinnacle 345' roadmap and the USD 300M+ CDMO contract remain key long-term drivers.
⚠ அபாய எச்சரிக்கைகள்
Pricing volatility in acetyls and pyridine derivatives
Detailed P&L figures omitted from cover document text
👀 கவனிக்க வேண்டியவை
Check the detailed financial tables in the accompanying exchange attachment to track EBITDA margin trends and revenue growth compared to Q1 FY27 revenue of Rs 1,300.27 Cr.
Jubilant Ingrevia to Incorporate WOS with ₹10 Cr Capital for 40% Stake in Zettaone
Jubilant Ingrevia's Board approved the incorporation of a wholly owned subsidiary (WOS), Jubilant Advanced Electronics Limited, with an initial subscription capital of up to ₹10 crore. This new entity will serve as the vehicle to execute the previously announced acquisition of a 40% strategic stake in Zettaone Technologies India Private Limited. The restructuring is aimed at building an integrated presence across electronics manufacturing services (EDMS) and semiconductor chemicals under the company's 'Pinnacle' growth strategy. Relative to Jubilant Ingrevia's TTM revenue of ₹4,651 crore and net worth of ₹2,640 crore, the initial ₹10 crore equity commitment is minor (<0.4% of net worth).
உச்சம் நம்பிக்கை
என்ன மாறியதுThe planned 40% strategic stake purchase in Zettaone will now be held via a newly formed wholly owned subsidiary rather than directly by Jubilant Ingrevia.
ஏன் இது முக்கியம்Creates a distinct corporate entity to house semiconductor and electronics manufacturing operations, separating it from the core specialty chemical intermediates business.
WOS Initial Subscription Capital: Up to Rs.10,00,00,000/-Initial Capital vs Net Worth: ~0.38%Stake in Zettaone: 40%Share Face Value: Rs 10/- each
📅 குறுகிய காலம்Neutral trading impact as the ₹10 crore initial capital commitment is small and represents an operational restructuring of a previously disclosed deal.
📈 நீண்ட காலம்Provides strategic separation and operational flexibility to scale its high-margin electronics and semiconductor solutions alongside the Pinnacle growth roadmap.
⚠ அபாய எச்சரிக்கைகள்
Execution and integration risks in the unfamiliar EDMS sector
Final transaction consideration for the 40% Zettaone stake remains undisclosed
👀 கவனிக்க வேண்டியவை
Track the completion timeline for the incorporation and subsequent formal closing of the 40% equity acquisition in Zettaone Technologies, alongside capital allocation details.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
₹189.2 Cr Stake Buy: Jubilant Ingrevia to Acquire 40% in Zettaone Technologies
Jubilant Ingrevia has entered into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Pvt. Ltd. for approximately ₹189.2 crore in cash. Zettaone is an electronics design and manufacturing platform (EDMS) with FY26 turnover of ₹98.1 crore (growing from ₹51.1 crore in FY24). The transaction will be completed in two tranches—tranche 1 by November 2026 and tranche 2 by September 2027—making Zettaone an associate company. This investment aligns with Jubilant Ingrevia's 'Pinnacle' strategy to build an integrated value chain across electronics and semiconductor spaces.
உச்சம் நம்பிக்கை
என்ன மாறியதுJubilant Ingrevia approved acquiring a 40% strategic stake in EDMS platform Zettaone Technologies for ₹189.2 crore.
ஏன் இது முக்கியம்Enables the specialty chemical and CDMO player to expand into electronics and semiconductor manufacturing services, capturing higher-value deep-tech supply chains.
Acquisition Cost: ₹189.2 கோடிStake Acquired: 40%Target FY26 Turnover: ₹98.1 கோடிTarget FY25 Turnover: ₹79.1 கோடிCost vs Net Worth: ~7.2%Tranche 1 Completion: நவம்பர் 2026
📅 குறுகிய காலம்Positive sentiment as the company takes a concrete step toward expanding its high-margin semiconductor and EDMS footprint without straining its balance sheet.
📈 நீண்ட காலம்Enhances long-term capability to provide integrated high-tech hardware, PCB design, and semiconductor chemical solutions, supporting the company's Pinnacle growth roadmap.
⚠ அபாய எச்சரிக்கைகள்
Integration risk and business model alignment between chemical CDMO and electronics hardware design
Two-tranche closing timeline extends execution out to September 2027
👀 கவனிக்க வேண்டியவை
Track the closure of Tranche 1 by November 2026 and monitor synergy disclosures regarding CDMO cross-selling into semiconductor and electronics sectors in upcoming earnings calls.
Jubilant Ingrevia reported a strong start to FY27 with revenue growing 25% YoY to Rs 1,300 crore, a 15-quarter high. EBITDA increased 36% YoY to Rs 209 crore, driven by a massive 240% surge in the Chemical Intermediates segment and steady 26% margins in Specialty Chemicals. The company confirmed its 'Pinnacle 345' growth strategy, supported by a $300M+ 5-year CDMO contract with take-or-pay protection and a pipeline of 100+ molecules with Rs 3,500+ crore peak revenue potential. Management expects sequential improvements throughout the year as new capacities like the Gajraula MPP commission by late 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has moved from a period of margin compression to a volume-led recovery across all segments, particularly in Chemical Intermediates and Nutrition.
ஏன் இது முக்கியம்The strong performance validates the company's transition toward high-margin Specialty Chemicals and CDMO services, reducing its historical dependence on cyclical commodity chemicals.
📅 குறுகிய காலம்The stock may see positive sentiment following the 15-quarter high revenue and significant EBITDA recovery in the intermediates segment.
📈 நீண்ட காலம்The 'Pinnacle 345' plan to triple revenue and quadruple EBITDA over 5 years is supported by a strong CDMO funnel and upcoming high-tech semiconductor chemical facilities.
⚠ அபாய எச்சரிக்கைகள்
Pricing pressure in Pyridine and Picolines
Geopolitical disruptions in the Middle East affecting supply chains
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of the Gajraula MPP and the Bharuch CDMO Agro plant, as these are critical to fulfilling the $300M+ contract and achieving the 'Pinnacle 345' revenue targets.
41% PAT Growth: Jubilant Ingrevia Reports 15-Quarter High Revenue of ₹1,300 Cr in Q1 FY27
Jubilant Ingrevia delivered a strong Q1 FY27 with revenue growing 25% YoY to ₹1,300 crore, driven by robust demand in Chemical Intermediates and Nutrition segments. PAT surged 41% YoY to ₹106 crore, while EBITDA margins expanded to 16% from 15% in the previous year. The company reported a significant recovery in Chemical Intermediates EBITDA, which grew 240% YoY to ₹57 crore. Management highlighted a robust CDMO/Fine Chemicals pipeline of 100+ molecules with a peak revenue potential exceeding ₹3,500 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a period of margin pressure to strong growth, achieving its highest revenue in nearly four years and significant margin recovery in the Intermediates segment.
ஏன் இது முக்கியம்The results validate the company's diversified business model and its ability to pass through input costs, while the expanding CDMO pipeline provides long-term revenue visibility beyond cyclical chemical products.
📅 குறுகிய காலம்The stock is likely to react positively to the 15-quarter high revenue and the sharp 240% YoY jump in Chemical Intermediates EBITDA.
📈 நீண்ட காலம்The 'Pinnacle 345' plan to triple revenue and quadruple EBITDA over 5 years remains the structural driver, supported by entry into high-tech semiconductor chemicals.
⚠ அபாய எச்சரிக்கைகள்
Pricing pressure in Pyridine
Geopolitical disruptions in the Middle East affecting supply chains
👀 கவனிக்க வேண்டியவை
Watch for the commissioning of the new Multi-Purpose Plant (MPP) by late 2026 and the ramp-up of the USD 300M+ CDMO contract which is critical for the 'Pinnacle 345' growth strategy.
Jubilant Ingrevia Q1 Revenue up 25% YoY to Rs 1,300 Cr; Net Profit Margin expands to 5.83%
Jubilant Ingrevia reported a strong start to FY27 with consolidated revenue from operations reaching Rs 1,300.27 Cr, a 25.3% increase over the same quarter last year. Profitability showed significant improvement as net profit margins expanded to 5.83% from 4.05% in Q1 FY26. The company's balance sheet remains robust with a net worth of Rs 2,770.67 Cr and a conservative debt-to-equity ratio of 0.23. This performance reflects the company's progress toward its 'Pinnacle 345' strategy, supported by volume growth and cost-saving initiatives.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has demonstrated a significant YoY recovery in both top-line growth and profit margins, moving past the pricing pressures seen in previous quarters.
ஏன் இது முக்கியம்The margin expansion indicates that the shift toward high-value Specialty Chemicals and CDMO services is beginning to offset cyclicality in the basic chemical intermediates segment.
📅 குறுகிய காலம்The stock may see positive momentum in the coming weeks as the market reacts to the 25% YoY revenue growth and margin improvement.
📈 நீண்ட காலம்The structural growth story remains intact, driven by the 'Pinnacle 345' plan to triple revenue and quadruple EBITDA over five years through high-tech chemical entries.
⚠ அபாய எச்சரிக்கைகள்
Pricing volatility in Pyridine and Picolines
Geopolitical risks affecting international trade (47% export share)
Execution risk of large-scale CDMO contracts
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the USD 300M+ CDMO contract starting in 2026 and the commissioning of the new Multi-Purpose Plant in Gajraula expected by late 2026.
Jubilant Ingrevia Reports Highest Q4 Revenue in 14 Quarters; EBITDA Up 11% YoY to ₹172 Cr
Jubilant Ingrevia reported a strong Q4 FY26 with revenue reaching ₹1,179 crore, a 12% YoY increase, and PAT rising 17% to ₹86 crore. The Specialty Chemicals segment achieved record quarterly revenue of ₹516 crore with stable 27% margins, while the Nutrition segment saw a 21% YoY revenue jump. Management highlighted the successful acquisition of Remidex Pharma and a robust CDMO pipeline of 100+ opportunities with a ₹3,500 crore potential. The company's leverage improved significantly, with Net Debt/EBITDA dropping to 0.99x.
முக்கிய அம்சங்கள்
Q4 FY26 revenue grew 12% YoY to ₹1,179 crore, the highest in 14 quarters.EBITDA for the quarter stood at ₹172 crore, up 11% YoY and 26% QoQ.Specialty Chemicals segment maintained a 27% EBITDA margin for the sixth consecutive quarter.Net Debt/EBITDA ratio improved to 0.99x, with net debt reducing by 11% in FY26.CDMO pipeline includes 100+ opportunities with a total potential of ₹3,500 crore.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the CDMO business and the integration of Remidex Pharma, as management expects sequential growth to continue into FY27. The stock remains attractive due to improving margins and a strengthening balance sheet.
Jubilant Ingrevia Q4 FY26 PAT Rises 17% YoY to ₹86 Cr; Total Dividend at ₹5 per Share
Jubilant Ingrevia reported a strong Q4 FY26 with revenue growing 12% YoY to ₹1,179 crore, marking its highest revenue in 14 quarters. Profit After Tax (PAT) increased 17% YoY to ₹86 crore, supported by a 10% volume growth and effective cost pass-through despite global supply chain disruptions. The Specialty Chemicals segment maintained robust margins of 27%, while the Nutrition business saw a 21% revenue jump. The company also improved its balance sheet, reducing net debt by 11% and achieving a healthy Net Debt/EBITDA ratio of 0.99x.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue reached ₹1,179 crore, a 12% YoY increase driven by 10% volume growth.EBITDA for the quarter stood at ₹172 crore, up 11% YoY and 26% sequentially (QoQ).Board recommended a final dividend of ₹2.50 per share, bringing the total FY26 dividend to ₹5 per share (500%).Specialty Chemicals segment EBITDA grew 21% in FY26, now contributing 75% to the total company EBITDA.Net Debt decreased by 11% in FY26, resulting in a significantly improved Net Debt/EBITDA ratio of 0.99x.
👀 கவனிக்க வேண்டியவை
Investors should note the strong volume recovery and margin stability in the Specialty Chemicals and CDMO segments as evidence of the 'Pinnacle' strategy's success. The reduction in debt and consistent dividend payout make it a compelling watch for long-term growth in the specialty chemicals space.
Jubilant Ingrevia Recommends 250% Final Dividend of Rs 2.50 Per Share for FY26
Jubilant Ingrevia Limited has announced a final dividend of Rs 2.50 per equity share, representing a 250% payout on its Re 1 face value for the financial year ended March 31, 2026. The company has established July 24, 2026, as the record date for determining eligibility, with the payout expected within 30 days of the AGM. Alongside the dividend, the board confirmed the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the 2026-27 fiscal year. This move signals a stable financial outlook and a consistent shareholder reward policy.
முக்கிய அம்சங்கள்
Recommended a final dividend of 250% amounting to Rs 2.50 per equity share of Re 1 face valueFixed Friday, July 24, 2026, as the record date for the purpose of final dividend paymentRe-appointed M/s J.K. Kabra & Co. as Cost Auditors for the financial year 2026-27The dividend payout is subject to shareholder approval at the upcoming Annual General Meeting
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold the shares before the record date of July 24, 2026. The 250% dividend payout indicates a healthy cash flow position and management's commitment to returning value to shareholders.
Jubilant Ingrevia Completes 100% Acquisition of Remidex Pharma Private Limited
Jubilant Ingrevia Limited has successfully finalized the acquisition of a 100% equity stake in Remidex Pharma Private Limited. This transaction follows the initial Share Purchase Agreement announced on March 13, 2026. The acquisition was completed on March 30, 2026, effectively making Remidex a wholly-owned subsidiary of the company. This move aligns with the company's strategic growth objectives in the pharmaceutical and chemical ingredients space.
முக்கிய அம்சங்கள்
Acquired 100% equity stake in Remidex Pharma Private LimitedTransaction completed on March 30, 2026, at 6:05 PM ISTFollows the initial disclosure and agreement dated March 13, 2026Remidex Pharma is now a wholly-owned subsidiary of Jubilant Ingrevia
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward inorganic growth and monitor the integration's impact on consolidated margins. Watch for further details on synergy benefits in the next quarterly earnings call.
Jubilant Ingrevia President of Speciality Chemicals Ambrish Dixit Resigns Effective March 31
Mr. Ambrish Dixit, the President of the Speciality Chemicals division at Jubilant Ingrevia, has resigned from his position. His departure is scheduled for the close of business hours on March 31, 2026. The company stated the reason for his resignation is to pursue a better professional opportunity. As Speciality Chemicals is a significant business segment for the company, investors should monitor the transition and the appointment of a successor.
முக்கிய அம்சங்கள்
Mr. Ambrish Dixit resigned as President of the Speciality Chemicals division on March 26, 2026.The resignation will take effect from the close of business hours on March 31, 2026.The official reason cited for the departure is the pursuit of a better opportunity.The announcement was made in compliance with Regulation 30 of SEBI LODR Regulations.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements regarding a replacement for the Speciality Chemicals leadership role. While management turnover is common, leadership stability in high-margin segments is key to maintaining operational momentum.
Jubilant Ingrevia Starts Commercial Production of Agro Intermediate at Bharuch Site
Jubilant Ingrevia's wholly-owned subsidiary, Jubilant Agro Sciences Limited, has officially commenced commercial production of an Agro Intermediate at its Bharuch facility. This production is part of a strategic CDMO contract with a leading global agrochemical company. The company confirmed that the dispatch of materials has already begun as of March 21, 2026. This development marks a significant milestone in the company's specialty chemicals and CDMO growth trajectory.
முக்கிய அம்சங்கள்
Commencement of commercial production of Agro Intermediate at the Bharuch site on March 21, 2026Production is linked to a specific CDMO contract with a leading global Agrochemical CompanyImmediate dispatch of materials started on the same day as the announcementExecuted through wholly-owned subsidiary Jubilant Agro Sciences Limited
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming quarterly results for the revenue contribution from this new production line. This development strengthens the company's position in the high-margin CDMO segment and validates its execution capabilities.
Jubilant Ingrevia to Acquire 100% Stake in Remidex Pharma for Rs 16.5 Crore
Jubilant Ingrevia Limited has entered into a Share Purchase Agreement to acquire a 100% stake in Remidex Pharma Private Limited for a cash consideration of Rs 16.5 crore. Remidex is a Bangalore-based manufacturer of micronutrient premixes and nutraceuticals with a turnover of Rs 24.27 crore in FY 2024-25. This acquisition is a strategic move to help Jubilant Ingrevia move forward in the value chain within the Human Nutrition space, leveraging its existing leadership in Vitamins B3 and B4. The deal is expected to be completed within 30 days, making Remidex a wholly-owned subsidiary.
முக்கிய அம்சங்கள்
Acquisition of 100% equity stake in Remidex Pharma for a cash consideration of Rs 16.5 crore.Remidex reported a turnover of Rs 24.27 crore for FY 2024-25, compared to Rs 31.15 crore in FY 2023-24.Strategic integration to expand into the Human Nutrition premix market using existing Vitamin B3 and B4 production.Target entity operates a high-grade manufacturing facility in Bangalore with WHO-GMP and FSSC certifications.The acquisition is expected to be finalized within an indicative period of 30 days.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of Remidex as it represents a strategic shift toward higher-margin value-added products in the nutrition segment. While the acquisition size is small relative to Jubilant's scale, it strengthens their competitive position in the nutraceutical supply chain.
Jubilant Ingrevia reported stable Q3 FY26 revenue of INR 1,051 crore, supported by a 9% year-on-year volume growth that offset softer global pricing. The company declared an interim dividend of 250% (INR 2.5 per share) and highlighted a robust opportunity funnel of over 100 projects with a peak revenue potential of INR 3,500 crore. While quarterly EBITDA dipped 8% to INR 136 crore due to pricing headwinds, the 9-month EBITDA rose 8% to INR 436 crore. Management expects growth to accelerate in Q4 FY26, driven by the commencement of a major CDMO order and new capacity expansions.
முக்கிய அம்சங்கள்
Achieved 9% YoY volume growth in Q3 FY26, marking the second-highest volumes in the last 12 quarters.Declared an interim dividend of 250%, translating to INR 2.5 per equity share.Specialty Chemicals segment maintained resilient margins above 25% despite intense global pricing pressure.Secured 16 new molecule wins during the year with an estimated peak revenue potential of INR 1,400 crore.Renewable energy share increased to 34%, contributing to a 10% YoY reduction in power and fuel expenses.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's transition toward high-margin CDMO and specialty segments, with Q4 FY26 being a critical period for new order execution. The stock is a 'Watch' for signs of recovery in global chemical pricing which could further boost EBITDA margins.
Jubilant Ingrevia Q3 FY26: PAT at ₹47 Cr; Declares ₹2.5 Interim Dividend Amid Pricing Pressure
Jubilant Ingrevia reported a mixed Q3 FY26 with revenue of ₹1,051 crore, down 1% YoY, as strong volume growth was offset by global pricing pressures. While quarterly PAT fell 32% YoY to ₹47 crore due to a one-time exceptional labor code expense, 9M FY26 performance remains positive with EBITDA up 8% YoY. The company declared an interim dividend of ₹2.5 per share (250%) and highlighted a robust CDMO pipeline with a peak revenue potential of ₹3,500 crore. Management remains optimistic about Q4, citing the commissioning of the $300 million Agro-Innovator project.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue stood at ₹1,051 Cr, with EBITDA margins holding steady at 13% despite global pricing headwinds.Board declared an interim dividend of 250% (₹2.5 per equity share) for the financial year 2025-26.CDMO pipeline expanded to 100+ active opportunities with a peak annual revenue potential of ₹3,500 Cr.The $300 million Agro-Innovator project is on track for Q4 FY26 commissioning with dispatches starting March 2026.Specialty Chemicals segment maintained resilient margins above 25% despite price volatility in Pyridine and Picolines.
👀 கவனிக்க வேண்டியவை
Investors should focus on the upcoming commissioning of the Agro-Innovator project and the conversion of the ₹3,500 Cr CDMO pipeline as primary growth catalysts. While short-term pricing pressure persists, the company's volume growth and cost-efficiency measures provide a margin cushion.
Jubilant Ingrevia Declares Interim Dividend of Rs 2.50 Per Share; Record Date Feb 10
Jubilant Ingrevia Limited has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. This dividend is applicable to shares with a face value of Re 1 each. The company has designated February 10, 2026, as the record date for identifying eligible shareholders. Shareholders can expect the dividend payment or dispatch to occur on or before March 4, 2026.
முக்கிய அம்சங்கள்
Interim dividend of Rs 2.50 per equity share (250% of face value).Record date for dividend eligibility set for February 10, 2026.Dividend payment to be completed on or before March 4, 2026.Board meeting concluded on February 4, 2026, to approve the payout.
👀 கவனிக்க வேண்டியவை
Existing shareholders should ensure they hold the stock before the ex-dividend date to qualify for the Rs 2.50 payout. New investors may consider the dividend yield relative to the current stock price.
Jubilant Ingrevia Q3 FY26 Net Profit Dips 5.6% YoY to ₹65.4 Crore; Revenue Flat
Jubilant Ingrevia reported a consolidated net profit of ₹65.41 crore for Q3 FY26, a 5.6% decline from ₹69.30 crore in the same quarter last year. Revenue from operations remained stagnant at ₹1,050.99 crore compared to ₹1,056.77 crore YoY. Sequentially, the company saw a 6.2% drop in revenue and a 5.8% decline in profit compared to Q2 FY26. Despite the quarterly dip, the nine-month performance remains stronger than the previous year, with PAT up 21% at ₹209.65 crore.
முக்கிய அம்சங்கள்
Consolidated Net Profit for Q3 FY26 stood at ₹65.41 crore vs ₹69.30 crore YoY.Total Revenue from operations was ₹1,050.99 crore, showing a marginal decline of 0.5% YoY.Nutrition & Health Solutions segment grew by 5.9% YoY to ₹200.76 crore.Speciality Chemicals segment revenue declined slightly to ₹457.57 crore from ₹467.64 crore YoY.Nine-month (9M FY26) PAT increased significantly to ₹209.65 crore from ₹172.90 crore in 9M FY25.
👀 கவனிக்க வேண்டியவை
The quarterly results indicate a temporary slowdown in the Speciality Chemicals and Intermediates segments. Investors should hold for long-term recovery while monitoring global chemical pricing trends and margin stability.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
